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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Serum alanine aminotransferase (ALT) concentration is the most
commonly used marker for hepatocellular injury. We investigated
the suitable cutoff value of serum ALT for the diagnosis or predic 
tion of fatty liver. In 1578 Japanese adults (1208 men, 370 women;
35–69 years of age) who visited our center both in 2000 and
between April 2007 and March 2008 (2007–2008), serum ALT con 
centration was an independent predictor of fatty liver in men in
2000 and in both sexes in 2007–2008. A significant increase in the
frequency of fatty liver was detected in participants with elevated
serum ALT concentrations, and serum levels of ALT in 2000 were
associated with fatty liver in 2007–2008 when the cutoff value
was set at 30 IU/L in men and 19 IU/L in women. The frequency of
fatty liver in 2007–2008 was significantly lower in participants
without fatty liver in 2000 whose serum ALT decreased between
2000 and 2007–2008. Our results suggest that serum ALT might be
not only an indicator of fatty liver but also a predictor of the
regression of fatty liver, and cutoff values of serum ALT of 30 IU/L
in men and 19 IU/L in women are suitable for the screening of
fatty liver.
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Introduction Serum alanine aminotransferase (ALT) is a cytosolic enzyme
that catalyzes the transfer of an amino group from alanine to
ketoglutarate to form pyruvic acid and glutamate, respectively,
and is the most commonly used marker for hepatocellular
injury.(1,2) Although the absolute amount is less than that of
aspartate aminotransferase (AST), a greater proportion is present
in the liver compared with heart and skeletal muscles. Therefore,
an increase in serum ALT concentration is more specific for liver
damage than an increase in AST concentration.(3) In patients with
alcoholic and non-alcoholic fatty liver disease (NAFLD), mild to
moderate elevation of serum ALT concentration is usually seen.(3,4)
The upper normal limit for serum ALT concentration has
usually been set around 40 IU/L, which was defined two decades
ago by studying general populations that included covert liver
pathological conditions such as chronic hepatitis C and NAFLD.(2)
In 2002, Prati et al.(1) proposed new ALT upper normal limits for
healthy men and women of 30 IU/L and 19 IU/L, respectively, by
studying 6835 first-time blood donors who were negative for anti-
hepatitis C virus (HCV) antibody and who had no contraindica-
tions to donation. Regarding NAFLD, Kunde et al.(2) supported
this proposition because lowering the cutoff value of serum ALT
significantly increased the detection of NAFLD in obese women.
Chang et al.(5) also reported that increased serum ALT concentra-
tion, even below the usual upper normal limit, was an independent
predictor of NAFLD in healthy, nondiabetic Korean men.
However, the implication of serum ALT concentration in the pre-
diction of development or regression of fatty liver is still unclear.
In the present study, we aimed to investigate whether the
usually accepted upper normal limit of serum ALT concentration
(around 40 IU/L) or recently proposed cutoff values (30 IU/L for
men and 19 IU/L for women)(1) would be suitable as an indicator
or predictor of fatty liver in 1578 participants who visited the
Health Service Center, Mitsubishi Heavy Industries, Ltd., Nagasaki
Shipyard and Machinery Works Hospital, Nagasaki, Japan for a
thorough medical examination between January and December
2000, and also re-visited the same center between April 2007 and
March 2008.(6,7)
Materials and Methods
Study participants. As reported in our previous publica-
tions,(6,7) the participants in the present study were 1578 Japanese
adults (1208 men and 370 women; mean age, 54.0 ± 4.7 years;
range, 35–69 years) who visited the Health Service Center,
Mitsubishi Heavy Industries, Ltd., Nagasaki Shipyard and
Machinery Works Hospital, Nagasaki, Japan for a thorough
medical examination between January and December 2000 (in
2000), and also re-visited the same center between April 2007
and March 2008 (in 2007–2008). The medical examination was
performed for subjects who visited the hospital voluntarily (most
of them were employees or family members of employees) to
promote public health through the early detection of chronic
diseases. According to our inclusion criteria,(6,7) all participants
were negative for hepatitis B surface antigen and anti-HCV
antibody. They also underwent abdominal ultrasonography (USG)
in both 2000 and 2007–2008. This study was performed according
to the principles of the Declaration of Helsinki. The study protocol
was approved by the Ethical Committees of Siebold University
of Nagasaki and Mitsubishi Heavy Industries, Ltd., Nagasaki
Shipyard and Machinery Works Hospital. Informed consent was
obtained from all participants.
Data collection and measurements. The medical examina-
tion was performed between 8:00–11:00 am after overnight
fasting. The information obtained from the medical records for the
present study included sex, age, height, body weight, history of
alcohol intake, systolic blood pressure (SBP), diastolic blood
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pressure (DBP), serum levels of aspartate aminotransferase
(AST), alanine aminotransferase (ALT), γ-glutamyl transpeptidase
(GGTP), total cholesterol (T.Chol.), triglyceride (TG), uric acid
(UA), fasting blood glucose (FBG), percentage body fat (% fat
volume), and liver status by USG in both 2000 and 2007–2008. In
2007–2008, information about the present physical exercise habit
and history of medical treatment for hypertension, dyslipidemia,
and/or diabetes mellitus was also obtained. Standard biochemical
tests including those for liver enzymes were performed on a
multichannel autoanalyzer.
Information on the history of alcohol intake, present physical
exercise habit, and history of medical treatment for hypertension,
dyslipidemia and/or diabetes mellitus was collected by a question-
naire. Different questionnaire formats were used in 2000 and
2007–2008. The history of alcohol intake was divided into two
groups in 2000 as follows: non-drinker (never drink or occasion-
ally drink 1–4 times per week) and daily drinker (at least 23 g/day
of alcohol intake 5–7 times per week).(6) In 2007–2008, the history
of alcohol intake was divided into three groups as follows: never
drinker, heavy drinker (at least 70 g/day of alcohol intake more
than 5 times per week), and moderate drinker (neither never
drinker nor heavy drinker).(7) Regarding the present physical
exercise habit, participants marked “yes” if they had a habit of
physical exercise such as jogging, walking, or playing tennis, golf,
or badminton. Regarding the history of medical treatment for
hypertension, dyslipidemia and/or diabetes mellitus, participants
marked “yes” if they had received medical treatment for any of the
diseases.
The body mass index (BMI) was calculated as body weight (kg)
divided by height squared (m2). Overweight was defined as a BMI
≥25 kg/m2.(8) The percentage body fat measurement was performed
using a bipedal bioimpedance instrument (Body Fat Analyzer
TBF-210 and TBF-202; Tanita, Tokyo, Japan). Obesity was defined
for Japanese adults as ≥25% body fat for men and ≥30% body fat
for women.(6)
Abdominal USG was performed by clinical hepatogastro-
enterologists or trained technicians without knowledge of the
anthropometric and laboratory data. When USG was performed
by a trained technician, one hepatogastroenterologist reviewed
the stored ultrasonographic images and made the final diagnosis.
The diagnosis of fatty liver by USG (Aloka SSD-2000 and Aloka
Pro Sound SSD-4000; Aloka, Tokyo) was based on the findings
of “bright liver” (increased echogenicity) with “liver-kidney
contrast” (increased echo level of the liver compared with the
right kidney). “Vascular blurring” (blurring of the hepatic vein)
and “deep attenuation” (attenuation of the echo level in the deep
region of the liver) were also seen in many cases, but their absence
did not exclude the diagnosis of fatty liver.
Because waist circumference and serum levels of high- and
low-density lipoprotein (HDL and LDL) cholesterol were not
available in our study participants, we defined a “tentative meta-
bolic syndrome” as follows: BMI ≥25 kg/m2 plus at least two of
the following three factors: (1) a high serum level of triglyceride
(≥150 mg/dL) or receiving specific treatment for triglyceride
abnormality; (2) high blood pressure (SBP ≥130 mmHg and/or
DBP ≥85 mmHg) or receiving specific treatment for hypertension;
(3) high FBG concentration (≥110 mg/dL) or receiving specific
treatment for glucose abnormality, as reported previously.(7)
Comparison of serum ALT data between 2000 and 2007–
2008. In the comparison of each participant’s serum ALT data
between 2000 and 2007–2008, “ALT reduction” and “ALT eleva-
tion” were defined as “(serum level of ALT in 2007–2008) <
(serum level of ALT in 2000)” and “(serum level of ALT in 2007–
2008) ≥ (serum level of ALT in 2000)”, respectively. “Change in
ALT between 2000 and 2007–2008” was calculated as follows:
(serum level of ALT in 2007–2008) – (serum level of ALT in
2000).
Statistical analysis. Data were expressed as mean ± standard
deviation (SD) or as median (range). Differences between groups
were examined for statistical significance using the two-tailed
Mann Whitney U test, Kruskal-Wallis test followed by Bonferroni’s
multiple comparison test, chi-square test, or Fisher’s exact proba-
bility test. Multivariate analysis was performed for variables that
were significant in univariate analyses using logistic regression
analysis. Correlations were examined by linear regression analysis
using the coefficient of correlation. All data analyses were
performed using IBM SPSS statistics, version 17.0 (IBM Co.,
Somers, NY) on a computer with a Windows operating system. A
p value less than 0.05 was considered statistically significant.
Results
Clinical and laboratory features of participants in 2000
and 2007–2008. The median interval in thorough medical
examinations between 2000 and 2007–2008 was 84.0 months
(range, 76–98 months). The mean age of participants in 2000 was
similar in men (47.1 ± 4.7 years; range, 34–62 years) and women
(45.5 ± 4.6 years; range, 29–58 years), but in 2007–2008, the age
was significantly higher in men (54.4 ± 4.7 years; range, 41–69
years) than in women (52.7 ± 4.6 years; range, 35–65 years)
(p<0.001). The number and frequency of participants for each
clinical and laboratory feature in 2000 and 2007–2008 are shown
in Table 1. The frequency of participants with fatty liver in 2007–
2008 (31.7%) was significantly higher than that in 2000 (22.7%).
Fatty liver was more frequently seen in men than in women in both
2000 (26.2% vs 11.1, p<0.001) and 2007–2008 (35.3% vs 20.0%,
p<0.001). The frequencies of participants with BMI excess
(≥25 kg/m2), diastolic hypertension, elevated AST, ALT, GGTP,
T.Chol., TG, UA, and FBG levels, and tentative metabolic
syndrome in 2007–2008 were also higher than those in 2000.
Body mass index, % fat volume, systolic and diastolic blood
pressure, and serum levels of AST, ALT, GGTP, T.Chol, TG, UA,
and FBG were higher in participants with fatty liver than in those
without fatty liver in both 2000 and 2007–2008. Participants who
had “tentative metabolic syndrome” in both 2000 and 2007–2008,
and who had received treatment for hypertension, dyslipidemia,
and/or diabetes mellitus in 2007–2008 were also more frequently
found in the fatty liver group. In contrast, there were no significant
difference in age or the proportion of alcohol drinker between the
fatty liver and non-fatty liver groups of participants in both 2000
and 2007–2008. Habitual physical exercise was more common in
the non-fatty liver group in 2007–2008(7) (data not shown).
Independent predictors of fatty liver in 2000 and 2007–
2008 by logistic regression analysis. The logistic regression
analysis showed that serum level of ALT was independent
predictor of fatty liver in men in 2000 and in both sexes in 2007–
2008. Serum levels of FBG and TG, and BMI were independent
predictors of fatty liver in both sexes in 2000 and in men in 2007–
2008. Additional independent predictors of fatty liver were serum
level of UA in men in 2000, tentative metabolic syndrome in
women in 2000, and % fat volume in both sexes in 2007–2008
(Table 2).
Serum ALT concentration and frequency of fatty liver.
In both 2000 and 2007–2008, the frequencies of fatty liver in men
whose serum level of ALT was ≤30 IU/L were significantly lower
than those in men whose serum level of ALT was 31–42 IU/L. In
2000, the frequency of fatty liver in men whose serum level of
ALT was 31–42 IU/L was also significantly lower than that in men
whose serum level of ALT was ≥43 IU/L. However, there was no
significant difference in the frequency of fatty liver between men
whose serum ALT level was 31–42 IU/L and ≥43 IU/L in 2007–
2008. In women, the frequencies of fatty liver whose serum
level of ALT was ≤19 IU/L were significantly lower than those in
women whose serum level of ALT was 20–42 IU/L, but there were
no significant differences in the frequency of fatty liver between
women whose serum ALT level was 20–42 IU/L and ≥43 IU/L indoi: 10.3164/jcbn.11 27
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Table 1. Number and frequency of participants for each clinical and laboratory feature in 2000 and 2007–2008 (n = 1578)
USG, ultrasonography; nd, not described; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGTP, gamma glutamyl transpeptidase; T.Chol., total
cholesterol; TG, triglyceride; UA, uric acid; FBG, fasting blood glucose; MS, metabolic syndrome; HT, hypertension; DL,
dyslipidemia; DM, diabetes mellitus.
Feature No. of subjects 
in 2000 (%)
No. of subjects 
in 2007–2008 (%) p
Fatty liver by USG 358 (22.7) 501 (31.7) <0.001
Alcohol consumption
Non drinker in 2000 705 (44.7)
Daily drinker in 2000 873 (55.3)
Never drinker in 2007–2008 365 (23.1)
Light to moderate drinker in 2007–2008 1098 (69.6)
Heavy drinker in 2007–2008 71 (4.5)
nd 44 (2.8)
Physical exercise habit
Yes 536 (34.0)
No 1031 (65.3)
nd 11 (0.7)
BMI ≥ 25 kg/m2 314 (19.9) 414 (26.2) <0.001
% fat volume excess (men and women) 441 (27.9) 596 (37.8) <0.001
% fat volume ≥ 25% (men) 326 (27.0) 349 (28.9) 0.297
% fat volume ≥ 30% (women) 115 (31.1) 128 (34.6) 0.309
SBP ≥ 130 mmHg 523 (33.1) 505 (32.0) 0.494
DBP ≥ 85 mmHg 395 (25.0) 194 (12.3) <0.001
AST ≥ 34 IU/L 103 (6.5) 145 (9.2) 0.005
ALT ≥ 43 IU/L 123 (7.8) 158 (10.0) 0.029
GGTP ≥ 48 IU/L 426 (27.0) 558 (35.4) <0.001
T.Chol. ≥ 220 mg/dL 515 (32.6) 637 (40.4) <0.001
TG ≥ 150 mg/dL 335 (21.2) 393 (24.9) 0.014
UA ≥ 7.6 mg/dL 104 (6.6) 167 (10.6) <0.001
FBG ≥ 110 mg/dL 142 (9.0) 302 (19.1) <0.001
Tentative MS 84 (5.3) 164 (10.4) <0.001
Receiving treatment for HT, DL, and/or DM 430 (27.2)
Table 2. Independent predictors of fatty liver by logistic regression analysis
CI, confidence interval. Refer to the legends of Table 1 for other abbreviations.
Variables Regression 
coefficient
Standard 
error p Adjusted 
odds ratio 95% CI
In 2000
Men (n = 1208)
ALT 0.061 0.010 <0.001 1.062 1.042–1.083
BMI 0.436 0.056 <0.001 1.546 1.386–1.725
FBG 0.030 0.006 <0.001 1.030 1.017–1.043
UA 0.222 0.075 0.003 1.248 1.078–1.445
TG 0.002 0.001 0.017 1.002 1.000–1.004
Women (n =3 7 0 )
BMI 0.779 0.156 <0.001 2.180 1.604–2.961
TG 0.023 0.006 <0.001 1.023 1.011–1.036
Tentative MS −2.420 0.730 0.001 0.089 0.021–0.372
FBG 0.084 0.029 0.005 1.086 1.026–1.150
In 2007–2008
Men (n = 1208)
ALT 0.042 0.009 <0.001 1.042 1.024–1.061
% fat volume 0.099 0.025 <0.001 1.104 1.051–1.161
BMI 0.276 0.050 <0.001 1.317 1.195–1.452
TG 0.002 0.001 0.003 1.002 1.001–1.004
FBG 0.013 0.005 0.004 1.013 1.004–1.023
Women (n =3 7 0 )
ALT 0.111 0.031 <0.001 1.117 1.052–1.187
% fat volume 0.197 0.061 0.001 1.218 1.080–1.374 J. Clin. Biochem. Nutr. | November 2011 | vol. 49 | no. 3 | 203
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both 2000 and 2007–2008 (Fig. 1).
Serum ALT concentration in 2000 and frequency of fatty
liver in 2007–2008. There was no significant difference in the
frequency of fatty liver in 2007–2008 between men with fatty liver
whose serum ALT level was ≤30 IU/L and ≥31 IU/L, and ≤42 IU/L
and ≥43 IU/L in 2000, respectively. Also, there was no significant
difference in the frequency of fatty liver in 2007–2008 between
women with fatty liver whose serum ALT level was ≤19 IU/L and
≥20 IU/L, and ≤42 IU/L and ≥43 IU/L in 2000, respectively.
Moreover, there were no significant differences in the frequency
of fatty liver in 2007–2008 between both men and women without
fatty liver whose serum ALT level was ≤42 IU/L and ≥43 IU/L in
2000. In contrast, the frequency of fatty liver in 2007–2008 was
significantly lower in participants without fatty liver whose serum
ALT level in 2000 was ≤30 IU/L in men and ≤19 IU/L in women
compared with ≥31 IU/L in men and ≥20 IU/L in women, respec-
tively (Table 3).
ALT reduction or elevation between 2000 and 2007–2008
and frequency of fatty liver in 2007–2008. There were no
significant differences in the frequency of fatty liver in 2007–2008
between both men and women with fatty liver whose serum ALT
reduced or elevated between 2000 and 2007–2008. However,
the frequency of fatty liver in 2007–2008 was significantly lower
in both men and women without fatty liver whose serum ALT
concentration decreased than in those whose serum ALT concen-
tration increased between 2000 and 2007–2008 (Table 4).
Change in ALT between 2000 and 2007–2008 and fre 
quency of fatty liver in 2007–2008. Change in serum ALT
concentration between 2000 and 2007–2008 was correlated with
the frequency of fatty liver in 2007–2008, especially in both men
and women without fatty liver in 2000. More than 50% of partici-
pants without fatty liver in 2000 whose serum ALT concentration
increased more than 20 IU/L between 2000 and 2007–2008 were
found to have fatty liver in 2007–2008, whereas the frequency of
fatty liver in 2007–2008 was up to 20% in participants whose
serum ALT concentration decreased more than 10 IU/L during the
period in both sexes (Fig. 2).
Discussion
Measurement of serum ALT concentration is used as a primary
screening test for the detection of liver diseases.(9) Alanine amino-
transferase is a hepatic, glucogenic enzyme that has been reported
to be related to visceral fat accumulation,(10) obesity,(11) metabolic
syndrome,(9,12,13) and insulin resistance.(14,15) In alcoholic and non-
alcoholic fatty liver disease, which is defined as an accumulation
of fat (mainly triglyceride) in liver cells, elevated serum ALT
concentration is considered to be a consequence of hepatocyte
damage.(5) Tiikkainen et al.(16) reported that the change in serum
ALT concentrations correlated with that in hepatic fat accumulation.
In the present longitudinal study, the frequency of participants
with fatty liver in 2007–2008 (31.7%) was significantly higher
than that in 2000 (22.7%), and the serum ALT concentration was
an independent predictor of fatty liver in men in 2000 and in both
sexes in 2007–2008. Kojima et al. reported that the prevalence of
fatty liver rose gradually from 12.6% in 1989 to 30.3% in 1998;
Fig. 1. Serum ALT concentration and frequency of fatty liver. ALT, alanine aminotransferase.doi: 10.3164/jcbn.11 27
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this was mainly due to an increase in BMI.(17) Hamaguchi et al.(18)
also reported that metabolic syndrome was a risk factor for the
development of NAFLD. Because some metabolism-related
factors such as BMI, % fat volume, and serum levels of FBG, TG,
and UA were also independent predictors of fatty liver,(7) serum
ALT concentration might be closely associated with metabolic
syndrome as stated above.
Serum ALT elevation has been used as a surrogate biomarker
for NAFLD.(19) Several studies have reported that elevated
serum ALT concentration was closely associated with fatty liver
even within the usually accepted normal reference interval.(1,2,5)
Therefore, we investigated in the present study whether the
usually accepted upper normal limit of serum ALT concentration
(around 40 IU/L) or recently proposed cutoff values (30 IU/L for
men and 19 IU/L for women)(1) would be suitable as an indicator
of fatty liver or predictor of the development or regression of
fatty liver. As a result, a significant increase in the frequency of
fatty liver was detected in participants with elevated serum ALT
concentrations when the cutoff value was set at 30 IU/L in men
and 19 IU/L in women. We further found that serum ALT concen-
trations in 2000 were associated with fatty liver in 2007–2008
when the cutoff value was set at 30 IU/L in men and 19 IU/L in
women. Moreover, the frequency of fatty liver in 2007–2008 was
significantly lower in participants without fatty liver whose serum
ALT reduced and the change in serum ALT concentration between
2000 and 2007–2008 was correlated with the frequency of fatty
liver in 2007–2008 in a dose-dependent manner, especially in both
men and women without fatty liver in 2000. These findings
suggest that upper normal serum ALT concentrations of 30 IU/L
in men and 19 IU/L in women are suitable for the effective
screening of fatty liver and that serum ALT concentration might
be not only an indicator of fatty liver, but also a predictor of the
regression, rather than the development, of fatty liver.
The mechanism of the above findings is still unclear. Uslan
Table 3. Relation between serum ALT concentration in 2000 and fatty liver in 2007–2008
ALT, alanine aminotransferase.
Serum ALT concentration in 2000
No. of subject in 2007–2008
p
Fatty liver (%) Non fatty liver (%)
Men with fatty liver in 2000
ALT ≤ 30 IU/L (n = 149) 117 (78.5) 32 (21.5) 0.889
ALT ≥ 31 IU/L (n = 168) 133 (79.2) 35 (20.8)
ALT ≤ 42 IU/L (n = 233) 181 (77.7) 52 (22.3) 0.391
ALT ≥ 43 IU/L (n = 84) 69 (82.1) 15 (17.9)
Women with fatty liver in 2000
ALT ≤ 19 IU/L (n = 21) 15 (71.4) 6 (28.6) 0.093
ALT ≥ 20 IU/L (n = 20) 19 (95.0) 1 (5.0)
ALT ≤ 42 IU/L (n = 35) 28 (80.0) 7 (20.0) 0.350
ALT ≥ 43 IU/L (n = 6) 6 (100) 0 (0)
Men without fatty liver in 2000
ALT ≤ 30 IU/L (n = 722) 139 (18.0) 633 (82.0) <0.001
ALT ≥ 31 IU/L (n = 119) 38 (31.9) 81 (68.1)
ALT ≤ 42 IU/L (n = 860) 169 (19.7) 691 (80.3) 0.399
ALT ≥ 43 IU/L (n = 31) 8 (25.8) 23 (74.2)
Women without fatty liver in 2000
ALT ≤ 19 IU/L (n = 279) 29 (10.7) 250 (89.3) 0.021
ALT ≥ 20 IU/L (n = 50) 11 (22.0) 39 (78.0)
ALT ≤ 42 IU/L (n = 315) 37 (11.7) 278 (88.3) 0.392
ALT ≥ 43 IU/L (n = 14) 3 (21.4) 11 (78.6)
Table 4. Relation between ALT reduction or elevation between 2000 and 2007–2008 and frequency of fatty liver in
2007–2008
ALT, alanine aminotransferase.
Change in serum ALT concentration 
between 2000 and 2007–2008
No. of subject in 2007–2008
p
Fatty liver (%) Non fatty liver (%)
Men with fatty liver in 2000
ALT reduction (n = 169) 127 (75.1) 42 (24.9) 0.083
ALT elevation (n = 148) 123 (83.1) 25 (16.9)
Women with fatty liver in 2000
ALT reduction (n = 12) 8 (66.7) 4 (33.3) 0.165
ALT elevation (n = 29) 26 (89.7) 3 (10.3)
Men without fatty liver in 2000
ALT reduction (n = 381) 56 (14.7) 325 (85.3) <0.001
ALT elevation (n = 510) 121 (23.7) 389 (76.3)
Women without fatty liver in 2000
ALT reduction (n = 99) 6 (6.1) 93 (93.9) 0.026
ALT elevation (n = 230) 34 (14.8) 196 (85.2) J. Clin. Biochem. Nutr. | November 2011 | vol. 49 | no. 3 | 205
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et al.(20) reported that weight loss in obese persons whose serum
ALT concentrations were within usually accepted normal limit
resulted in a decrease in serum ALT concentrations. Saito et al.(9)
reported that upper normal limits of serum ALT concentration of
30 IU/L in men and 25 IU/L in women were suitable for the
effective screening of individuals with metabolic syndrome in
Japanese population. Wannamethee et al.(21) also reported that
elevated serum ALT concentrations still within the normal range
were an independent predictor of type 2 diabetes in older men.
Oxidative stress plays a pivotal role in the pathogenesis of
metabolic syndrome including type 2 diabetes and NAFLD or
non-alcoholic steatohepatitis, and serum ALT concentration might
be closely associated with metabolic syndrome.(22) Therefore, even
a slight elevation of serum ALT concentration might reflect early
stage of metabolic syndrome and subclinical, i.e., ultrasono-
graphically undetectable, early hepatic fat accumulation.(5)
There were some limitations to the present study. First, fluctua-
tion of serum ALT concentration is normally seen over the course
of the day and ALT levels can also increase in response to
strenuous physical exercise. However, we compared the serum
ALT concentrations of only two timepoints in 2000 and 2007–2008
and the time-course of ALT concentrations during the follow-up
periods was not included. Therefore, fluctuating serum ALT
concentration was not considered. Second, liver biopsy, which is
the standard to establish a histopathological diagnosis of fatty
liver, was not performed. Whether early hepatic fat accumulation
is present in patients whose serum ALT concentrations are slightly
elevated would be of interest. Third, our criteria of “tentative
metabolic syndrome” were different from the generally accepted
criteria of metabolic syndrome.(7) A subsequent study should
include a detailed evaluation of metabolic syndrome that includes
the measurement of waist circumference and serum levels of HDL
and LDL cholesterol.
In conclusion, our data demonstrate that serum ALT concentra-
tion might be not only an indicator of fatty liver but also a pre-
dictor of the regression of fatty liver and that the upper normal
limits of serum ALT concentration of 30 IU/L in men and 19 IU/L
in women are suitable for the effective screening of fatty liver. Our
data might have clinical and public health implications because
the measurement of serum ALT concentration is used as a primary
screening test for the detection of liver diseases.(9) The exact
mechanism of increased serum ALT concentration in fatty liver
remained to be determined.
Fig. 2. Change in ALT between 2000 and 2007–2008 and frequency of fatty liver in 2007–2008. ALT, alanine aminotransferase; FL, fatty liver.doi: 10.3164/jcbn.11 27
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